2024 Q1 Form 10-Q Financial Statement
#000149315224019675 Filed on May 15, 2024
Income Statement
| Concept | 2024 Q1 | 2023 Q4 | 2023 Q1 |
|---|---|---|---|
| Revenue | $921.0K | $1.177M | $354.0K |
| YoY Change | 160.17% | 56.52% | 30.15% |
| Cost Of Revenue | $257.0K | $440.0K | $119.0K |
| YoY Change | 115.97% | -24.79% | -28.31% |
| Gross Profit | $664.0K | $737.0K | $235.0K |
| YoY Change | 182.55% | 341.32% | 121.7% |
| Gross Profit Margin | 72.1% | 62.62% | 66.38% |
| Selling, General & Admin | $1.111M | $1.377M | $1.235M |
| YoY Change | -10.04% | -71.88% | 7.2% |
| % of Gross Profit | 167.32% | 186.84% | 525.53% |
| Research & Development | $121.0K | $62.00K | $55.00K |
| YoY Change | 120.0% | -78.09% | -16.67% |
| % of Gross Profit | 18.22% | 8.41% | 23.4% |
| Depreciation & Amortization | $0.00 | $1.000K | $1.000K |
| YoY Change | -100.0% | ||
| % of Gross Profit | 0.0% | 0.14% | 0.43% |
| Operating Expenses | $1.232M | $1.439M | $1.290M |
| YoY Change | -4.5% | -72.21% | 5.91% |
| Operating Profit | -$568.0K | -$702.0K | -$1.055M |
| YoY Change | -46.16% | -85.99% | -5.13% |
| Interest Expense | $34.00K | -$100.0K | $34.00K |
| YoY Change | 0.0% | -75.06% | -361.54% |
| % of Operating Profit | |||
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | -$581.0K | -$802.0K | -$1.095M |
| YoY Change | -46.94% | -85.18% | -2.67% |
| Income Tax | $7.000K | $11.00K | $2.000K |
| % Of Pretax Income | |||
| Net Earnings | -$588.0K | -$813.0K | -$1.097M |
| YoY Change | -46.4% | -85.08% | -3.09% |
| Net Earnings / Revenue | -63.84% | -69.07% | -309.89% |
| Basic Earnings Per Share | -$0.23 | -$0.67 | |
| Diluted Earnings Per Share | -$0.23 | -$0.41 | -$0.66 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 2.510M shares | 2.046M shares | 1.652M shares |
| Diluted Shares Outstanding | 2.510M shares | 1.652M shares |
Balance Sheet
| Concept | 2024 Q1 | 2023 Q4 | 2023 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $2.700M | $3.283M | $1.512M |
| YoY Change | 78.57% | 21.01% | -74.76% |
| Cash & Equivalents | $2.700M | $3.283M | $1.512M |
| Short-Term Investments | |||
| Other Short-Term Assets | $297.0K | $154.0K | $782.0K |
| YoY Change | -62.02% | 54.0% | -14.16% |
| Inventory | $2.588M | $2.732M | $2.213M |
| Prepaid Expenses | $47.00M | ||
| Receivables | $360.0K | $318.0K | $58.00K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $5.945M | $6.487M | $4.565M |
| YoY Change | 30.23% | 15.65% | -38.23% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $8.000K | $12.00K | $7.000K |
| YoY Change | 14.29% | 71.43% | -85.71% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $1.000K | $175.0K | $5.000K |
| YoY Change | -80.0% | 5733.33% | -97.77% |
| Total Long-Term Assets | $290.0K | $187.0K | $246.0K |
| YoY Change | 17.89% | -30.74% | -9.89% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $5.945M | $6.487M | $4.565M |
| Total Long-Term Assets | $290.0K | $187.0K | $246.0K |
| Total Assets | $6.235M | $6.674M | $4.811M |
| YoY Change | 29.6% | 13.52% | -37.22% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $37.00K | $138.0K | $45.00K |
| YoY Change | -17.78% | 109.09% | -73.84% |
| Accrued Expenses | $24.00K | $5.000K | $55.00K |
| YoY Change | -56.36% | -93.83% | 25.0% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $2.427M | $2.454M | $2.289M |
| YoY Change | 6.03% | 5.96% | 14.05% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $304.0K | $232.0K | $319.0K |
| YoY Change | -4.7% | -29.7% | -19.24% |
| Total Long-Term Liabilities | $304.0K | $232.0K | $319.0K |
| YoY Change | -4.7% | -29.7% | -19.24% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.427M | $2.454M | $2.289M |
| Total Long-Term Liabilities | $304.0K | $232.0K | $319.0K |
| Total Liabilities | $2.731M | $2.686M | $2.608M |
| YoY Change | 4.72% | 1.51% | 8.58% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$66.68M | -$66.10M | -$63.48M |
| YoY Change | 5.04% | 5.95% | |
| Common Stock | $2.000K | $2.000K | $2.000K |
| YoY Change | 0.0% | 0.0% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $3.504M | $3.988M | $2.203M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $6.235M | $6.674M | $4.811M |
| YoY Change | 29.6% | 13.52% | -37.22% |
Cashflow Statement
| Concept | 2024 Q1 | 2023 Q4 | 2023 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$588.0K | -$813.0K | -$1.097M |
| YoY Change | -46.4% | -85.08% | -3.09% |
| Depreciation, Depletion And Amortization | $0.00 | $1.000K | $1.000K |
| YoY Change | -100.0% | ||
| Cash From Operating Activities | -$579.0K | -$492.0K | -$1.200M |
| YoY Change | -51.75% | -63.04% | -67.91% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $1.000K | $1.000K | $1.000K |
| YoY Change | 0.0% | -200.0% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$1.000K | -$1.000K | -$1.000K |
| YoY Change | 0.0% | -200.0% | |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 2.000K | $7.000K | |
| YoY Change | -99.9% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -$579.0K | -492.0K | -$1.200M |
| Cash From Investing Activities | -$1.000K | -1.000K | -$1.000K |
| Cash From Financing Activities | 2.000K | $7.000K | |
| Net Change In Cash | -$583.0K | -491.0K | -$1.201M |
| YoY Change | -51.46% | -164.44% | -67.89% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$579.0K | -$492.0K | -$1.200M |
| Capital Expenditures | $1.000K | $1.000K | $1.000K |
| Free Cash Flow | -$580.0K | -$493.0K | -$1.201M |
| YoY Change | -51.71% | -62.93% | -67.89% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2023Q1 | NAOV |
Stock Issued During Period Values Reverse Stock Splits
StockIssuedDuringPeriodValuesReverseStockSplits
|
shares | |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
usd | |
| CY2024Q1 | NAOV |
Stock Issued During Period Value Prefunded Warrants Exercised
StockIssuedDuringPeriodValuePrefundedWarrantsExercised
|
usd | |
| CY2024Q1 | NAOV |
Stock Issued During Period Values Reverse Stock Splits
StockIssuedDuringPeriodValuesReverseStockSplits
|
shares | |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
usd | |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
usd | |
| CY2023Q1 | us-gaap |
Noncash Contribution Expense
NoncashContributionExpense
|
usd | |
| CY2024Q1 | us-gaap |
Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
|
usd | |
| CY2024Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
usd | |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
usd | |
| CY2024Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
usd | |
| CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
usd | |
| CY2024Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
usd | |
| CY2023Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
usd | |
| CY2024Q1 | us-gaap |
Deferred Revenue
DeferredRevenue
|
46000 | usd |
| CY2023Q4 | us-gaap |
Deferred Revenue
DeferredRevenue
|
46000 | usd |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
40000000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
40000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
2784353 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
2784353 | shares |
| CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | usd |
| CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | usd |
| CY2024Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
70256000 | usd |
| CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
70149000 | usd |
| CY2024Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-70000 | usd |
| CY2023Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-67000 | usd |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-66684000 | usd |
| CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-66096000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3504000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3988000 | usd |
| CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
6235000 | usd |
| CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
6674000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
354000 | usd |
| CY2024Q1 | us-gaap |
Gross Profit
GrossProfit
|
664000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
121000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
55000 | usd |
| CY2024Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
165000 | usd |
| CY2023Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
214000 | usd |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
946000 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1021000 | usd |
| CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
1232000 | usd |
| CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
1290000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-568000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1055000 | usd |
| CY2024Q1 | us-gaap |
Interest Expense
InterestExpense
|
34000 | usd |
| CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
34000 | usd |
| CY2024Q1 | NAOV |
Financial Expenses Net
FinancialExpensesNet
|
21000 | usd |
| CY2023Q1 | NAOV |
Financial Expenses Net
FinancialExpensesNet
|
-6000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-581000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1095000 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
7000 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-588000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1097000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.23 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.23 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.67 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.67 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
2510309 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
2510309 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
1651936 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
1651936 | shares |
| CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-588000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-1097000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
|
-1000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
|
5000 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-587000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-1102000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3233000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
67000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
7000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-7000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1097000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2203000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3988000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3988000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
|
-3000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
107000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-588000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3504000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3504000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-588000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1097000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
107000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
67000 | usd |
| CY2024Q1 | us-gaap |
Noncash Contribution Expense
NoncashContributionExpense
|
34000 | usd |
| CY2023Q1 | us-gaap |
Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
|
2000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
42000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
49000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
143000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
70000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-144000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
38000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-101000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-21000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
21000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
41000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-11000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-32000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-579000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1200000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
7000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
7000 | usd |
| CY2024Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-3000 | usd |
| CY2023Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-7000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-583000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1201000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
3283000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2713000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2700000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
1512000 | usd |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p id="xdx_805_eus-gaap--NatureOfOperations_zo6Rj4ns685g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82D_z2xWvg9PnHie">DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix, Inc. (the “Company”), a Delaware corporation, commenced operations on October 20, 2003 and is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home without the assistance of medical professionals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s principal research and development activities are conducted in Israel through its wholly owned subsidiary, NanoVibronix (Israel 2003) Ltd., a company registered in Israel, which commenced operations in October 2003.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_84A_eus-gaap--UseOfEstimates_zwnOEBD7C8Hl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zBnrbWjOnHEl">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
|
6000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
|
7000 | usd |
| CY2024Q1 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
250000 | usd |
| CY2024Q1 | us-gaap |
Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
|
2166000 | usd |
| CY2024Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
360000 | usd |
| CY2024Q1 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
311000 | usd |
| CY2023Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
210000 | usd |
| CY2024Q1 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
2277000 | usd |
| CY2023Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
2522000 | usd |
| CY2024Q1 | us-gaap |
Inventory Net
InventoryNet
|
2588000 | usd |
| CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
2732000 | usd |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q1 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
1-for-20 Reverse Stock Split | |
| CY2023Q1 | us-gaap |
Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
|
15726 | shares |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8097879 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
220412 | shares |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8097879 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
220412 | shares |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
921000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
354000 | usd |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
921000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
354000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y11M8D | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.10 | pure |
| CY2024Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
6000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
18000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
31000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
44000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
45000 | usd |
| CY2024Q1 | NAOV |
Lessee Operating Lease Liability Payments Due After Year Two
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
|
6000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
126000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
16000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
110000 | usd |
| CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1000 | usd |
| CY2024Q1 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
2000 | usd |
| CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
2000 | usd |
| CY2024Q1 | us-gaap |
Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
|
2000 | usd |
| CY2023Q4 | us-gaap |
Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
|
1000 | usd |
| CY2021Q1 | us-gaap |
Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
|
3000000 | usd |
| CY2022Q1 | us-gaap |
Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
|
1500250 | usd |
| CY2022Q1 | us-gaap |
Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
|
1432000 | usd |
| CY2022Q1 | us-gaap |
Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
|
68250 | usd |
| CY2024Q1 | us-gaap |
Legal Fees
LegalFees
|
0 | usd |
| CY2023Q1 | us-gaap |
Legal Fees
LegalFees
|
76034 | usd |
